Safety Profile and Common Side Effects of GLP-1 Medications

Mechanism of Action and Types

GLP-1 receptor agonists stimulate glucose-dependent insulin secretion, reducing glucagon secretion in a glucose-dependent manner, delaying gastric emptying, and promoting satiety and reducing food intake via central appetite suppression, as recommended by the American Diabetes Association 2
Available GLP-1 receptor agonists include daily administration of liraglutide, lixisenatide, and exenatide twice daily, and weekly administration of dulaglutide, exenatide extended-release, and semaglutide, according to the American College of Cardiology 2
An oral formulation of semaglutide is also available, as noted by the Kidney International journal 3

Gastrointestinal side effects, including nausea, vomiting, and diarrhea, typically occur during the initial treatment phase and gradually diminish over time, as reported by the Diabetes/Metabolism Research and Reviews journal 1
These gastrointestinal symptoms may be more pronounced with certain agents, such as semaglutide, and can be managed with caution and monitoring, as recommended by the Journal of the American College of Cardiology 4

Contraindications for GLP-1 receptor agonists include a history of serious hypersensitivity reaction to the drug, personal or family history of medullary thyroid cancer, and multiple endocrine neoplasia syndrome type 2 (MEN2), as stated by the American College of Cardiology 4, 6
Caution is advised when using liraglutide in patients with a history of pancreatitis, and when using liraglutide and semaglutide in patients with severe renal impairment, as recommended by the Journal of the American College of Cardiology 4
Shorter-acting agents may delay gastric emptying and slow absorption of other medications, and caution is advised in patients with prior gastric surgery, as noted by the Diabetes/Metabolism Research and Reviews journal 1

Several GLP-1 receptor agonists, including liraglutide, semaglutide, and dulaglutide, have demonstrated cardiovascular benefits, reducing the risk of major adverse cardiovascular events in patients with type 2 diabetes, as reported by the Journal of the American College of Cardiology 1, 5
GLP-1 receptor agonists also reduce albuminuria and slow eGFR decline, with no increased risk of heart failure hospitalization observed in cardiovascular outcome trials, as noted by the Kidney International journal 3 and the Circulation journal 6

Exenatide and lixisenatide are contraindicated in severe renal impairment, while liraglutide and semaglutide should be used with caution, as stated by the American College of Cardiology 4
GLP-1 receptor agonists have shown benefits in patients with chronic kidney disease, and should be used with caution in patients with recent heart failure decompensation, as recommended by the Kidney International journal 3 and the Circulation journal 6
GLP-1 receptor agonists may decrease hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD), with semaglutide showing the most robust evidence for NASH resolution, as noted by the Gastroenterology journal 7

Monitor for signs of pancreatitis, and consider dose reduction of insulin or sulfonylureas when adding GLP-1 receptor agonists to prevent hypoglycemia, as recommended by the Journal of the American College of Cardiology 4
Monitor for retinopathy complications with semaglutide, especially with rapid glucose reduction, as noted by the Journal of the American College of Cardiology 4
GLP-1 receptor agonists are particularly beneficial for patients who need weight loss, and are effective as monotherapy or in combination with other antidiabetic drugs, with minimal risk of hypoglycemia when used alone, as reported by the Diabetes Care journal 2 and the Diabetes/Metabolism Research and Reviews journal 1